Phase I study combining PARP-inhibition with immune checkpoint blockade in women with BRCA-deficient recurrent ovarian cancer
Adams, S.F., Rixe, O., McCance, D., Lee, J.H., Eberhardt, S., Westgate, S., Rutledge, T., Muller, C.Volume:
145
Language:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2017.03.234
Date:
June, 2017
File:
PDF, 245 KB
english, 2017